The Quantellect read.As of Nov 19, 2026, 6 active firms cover Bright Minds Biosciences Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $145.00 to $220.00, a moderate spread. The average target of $161.40 sits 679% above the current $20.73. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.82 next quarter toward $-7.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$161.40
+678.6% upside
Average target across 5 active firms as of Nov 19, 2026 vs $20.73 current
Highest Target$220.00
Average Target$161.40
Lowest Target$145.00
Detailed analyst forecasts for DRUG
Showing 1–4 of 4 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate DRUG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DRUG EPS & revenue forecast
EPS · NEXT QUARTER
$-1.82
Range $-2.72 – $-1.21 · 5 analysts · +88% YoY
Next period, 5 analysts expect Bright Minds Biosciences Inc to earn $-1.82 a share (range $-2.72 – $-1.21), versus $-0.97 a year earlier. Full-year consensus is $-3.76, growing to $-7.63 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0)., rising to $0 next year.
Top analysts covering Bright Minds Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DRUG.
#1
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
No targeton DRUG
Overall win rate
35%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$145.00+599.5% to target
Overall win rate
36%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$220.00+961.3% to target
Overall win rate
30%
+ Follow
#4
Thomas Shrader
BTIG · Rank #553
Buy
$147.00+609.1% to target
Overall win rate
32%
+ Follow
#5
Andrew Tsai
Jefferies
Buy
$145.00+599.5% to target
Coverage
—
+ Follow
DRUG stock forecast FAQ
What is DRUG's average 12-month price target?+
The 5 active firms with a live target average $161.40 for Bright Minds Biosciences Inc over the next 12 months, ranging from a $220.00 high to a $145.00 low, as of Nov 19, 2026.
Is DRUG stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DRUG?+
The Street-high target is $220.00 (Piper Sandler), and the Street-low is $145.00 (HC Wainwright & Co.). The average of all 5 active-firm targets is $161.40.
How many active Wall Street firms cover DRUG?+
6 active firms have a recognized rating on Bright Minds Biosciences Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DRUG?+
Among analysts who currently cover DRUG, Pete Stavropoulos of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #300). Their current call is Buy.
What is Bright Minds Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-1.82 per share (range $-2.72 – $-1.21) across 5 analysts. Full-year EPS is projected at $-3.76, rising to $-7.63 the following year.
How much revenue is Bright Minds Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at —, growing to $0 next year.
Have analysts been upgrading or downgrading DRUG lately?+
As of Nov 19, 2026, 6 of 6 active firms rate DRUG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DRUG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.